15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering NextCure Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $18.00 to $25.00, so the covering firms are broadly aligned. The average target of $21.50 sits 273% above the current $5.76. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.79 next quarter toward $-5.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to NextCure Inc.
As of Aug, 2 of 2 firms rate NXTC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NXTC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.79
Range $-0.79 – $-0.79 · 1 analysts · -2% YoY
Next period, 1 analysts expect NextCure Inc to earn $-0.79 a share (range $-0.79 – $-0.79), versus $-0.81 a year earlier. Full-year consensus is $-6.73, growing to $-5.76 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering NextCure Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NXTC.
#1
Edward Tenthoff
Piper Sandler · Rank #327
Buy
$15.00+160.4% to target
Overall win rate
29%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #396
Buy
$20.00+247.2% to target
Overall win rate
23%
+ Follow
#3
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$18.00+212.5% to target
Coverage
—
+ Follow
#4
CL
Christopher Liu
LUCID CAPITAL MARKETS
Buy
$25.00+334.0% to target
Coverage
—
+ Follow
NXTC stock forecast FAQ
What is NXTC's average 12-month price target?+
The 2 analysts with a live target average $21.50 for NextCure Inc over the next 12 months, ranging from a $25.00 high to a $18.00 low.
Is NXTC stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NXTC?+
The Street-high target is $25.00 (LUCID CAPITAL MARKETS), and the Street-low is $18.00 (Ladenburg Thalmann). The average of all 2 active targets is $21.50.
How many Wall Street analysts cover NXTC?+
2 analysts have an active rating on NextCure Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NXTC?+
Among analysts who currently cover NXTC, Edward Tenthoff of Piper Sandler has the strongest overall Quantellect track record (Rank #327). Their current call is Buy with a $15.00 target.
What is NextCure Inc's projected EPS for next quarter?+
The consensus estimate is $-0.79 per share (range $-0.79 – $-0.79) across 1 analysts. Full-year EPS is projected at $-6.73, rising to $-5.76 the following year.
How much revenue is NextCure Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NXTC lately?+
As of Aug, 2 of 2 firms rate NXTC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NXTC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
